Form 4: Revolution Medicines CEO Sells Shares Under 10b5-1 Plan

Revolution Medicines, Inc. CEO Mark A. Goldsmith exercised stock options and subsequently sold 20,000 shares of common stock on November 18, 2025, as part of a pre-arranged 10b5-1 trading plan.

Summary

• Mark A. Goldsmith, President and CEO of Revolution Medicines, Inc., executed transactions on November 18, 2025.
• Goldsmith exercised 20,000 stock options at an exercise price of $4.09 per share.
• Concurrently, he sold 20,000 shares of common stock at a weighted average price of $70.3793 per share.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on December 19, 2024.
• Following these transactions, Goldsmith's direct beneficial ownership of common stock decreased from 267,863 shares to 247,863 shares, which includes 193,475 restricted stock units.
• He also holds indirect beneficial ownership through various trusts, totaling 710,898 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While insider selling can sometimes be viewed negatively, the execution under a pre-arranged 10b5-1 plan mitigates concerns about opportunistic trading. The significant profit from the option exercise reflects value creation for the executive.

Positives

• The exercise of stock options at a low price ($4.09) and subsequent sale at a significantly higher price ($70.3793) indicates a substantial personal gain for the CEO, reflecting past performance and value creation.
• The transactions were executed under a pre-arranged 10b5-1 trading plan, which demonstrates a proactive approach to managing personal holdings and mitigates concerns about opportunistic insider selling.

Negatives

• The sale of 20,000 shares by the President and CEO, even under a 10b5-1 plan, represents a reduction in direct insider ownership, which some investors might interpret as a lack of confidence, although this is often a routine liquidity event.

Risks

• No specific risks are mentioned in this Form 4 filing, as it primarily reports insider transactions.

Future Outlook

This Form 4 filing is a report of past insider transactions and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

Insider transactions, particularly those executed under Rule 10b5-1 plans, are common across all industries, including biotechnology. These plans allow insiders to sell shares at pre-determined times to avoid accusations of trading on material non-public information. The significant difference between the option exercise price and the sale price is typical for executives who have been with a company for an extended period and are monetizing long-held equity.

Comparison to Industry Standards

• This Form 4 filing details a routine insider transaction (exercise and sale) executed under a 10b5-1 plan. Such transactions are standard practice for executives across publicly traded companies, including those in the biotechnology sector.
• There are no specific comparable companies or projects mentioned in this filing to assess against industry benchmarks, as it focuses solely on personal stock transactions of an executive.

Related Party Transactions

• The filing notes indirect beneficial ownership through various trusts, including the Jonathan Goldsmith Revocable Trust, Rebecca Eve Goldsmith Trust, Rebecca Goldsmith Revocable Trust, and Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust. These are common arrangements for executive shareholdings and not typically considered 'related party transactions' in the context of company dealings, but rather personal estate planning.

Stakeholder Impact

• Shareholders: May observe a reduction in direct insider ownership, but the 10b5-1 plan context generally reduces negative interpretations. The transaction itself does not directly impact company operations or financial health.
• Employees, Customers, Suppliers, Creditors: No direct impact from this insider transaction report.

Next Steps

• No specific future actions, events, or milestones are mentioned in this Form 4 filing, as it reports completed transactions.

Key Dates

Keywords

Revolution Medicines, RVMD, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Mark A. Goldsmith, 10b5-1 Plan, CEO, Biotechnology